Syndax to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call and Webcast on March 3, 2025

Core Viewpoint - Syndax Pharmaceuticals will report its fourth quarter and full year 2024 financial results on March 3, 2025, along with a business update [1] Financial Results Announcement - The earnings release will be followed by a conference call and live audio webcast at 8:00 a.m. ET on the same day [2] - Access to the live audio webcast and slides will be available on the Company's website, with a replay accessible for 90 days post-call [2] Company Overview - Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company focused on developing innovative cancer therapies [3] - Key products in the pipeline include Revuforj (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody targeting the CSF-1 receptor [3] - The company is committed to advancing cancer care through various clinical trials [3]